NCT07036185View on ClinicalTrials.gov

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Gastric/Gastroesophageal Junction CancerBreast CancerColorectal CancerNon-small Cell Lung Cancer (NSCLC)Bile Duct CancerHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

KJ015 Injection (Subcutaneous Injection)

KJ015 is administered via subcutaneous injection, with the dosing frequency set at either Q3W.

Trial Locations (1)

200120

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Bao Pharmaceuticals Co., Ltd.

INDUSTRY